A case study on Sema3E-Fc aggregation and assay-dependent differences in quantitation.

Area of Science:

• Biochemistry
• Immunology
• Pharmacology

Background:

• Development of two enzyme-linked immunosorbent assays (ELISAs) to quantify serum concentrations of a novel antitumor agent, Sema3E IgG1 Fc fusion protein, in mice.
• A generic ELISA targeted the Fc portion, while a specific ELISA detected intact, receptor-binding protein.

Purpose of the Study:

• To investigate the discrepancy in serum concentrations observed between the generic and specific ELISAs.
• To characterize the stability and aggregation state of the Sema3E-Fc protein in vitro and in vivo.

Main Methods:

• Development and application of two distinct ELISA methods (generic and specific).
• Utilized size-exclusion High-Performance Liquid Chromatography (HPLC) and Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) for biophysical characterization.
• Combined immunochemical analysis with biophysical techniques.

Main Results:

• The generic ELISA consistently reported higher serum concentrations of Sema3E-Fc than the specific ELISA.
• Size-exclusion HPLC and SDS-PAGE revealed significant aggregation of the Sema3E-Fc protein.
• The generic assay showed higher recovery of Sema3E-Fc in the presence of protein aggregates compared to the specific assay.

Conclusions:

• Protein aggregation was identified as the cause for the discrepancy between the two ELISA methods.
• Biophysical characterization was crucial in understanding the protein instability and the source of assay variability.
• Accurate quantification of therapeutic proteins requires consideration of potential aggregation and the specificity of analytical assays.